MedCity News
Trial results add to uses for Exact Sciences test
The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy and those who won t. The latest trial results extend the test s reach.
Shares1
A clinical trial shows that a genomic test from diagnostics company Exact Sciences can help more women with early-stage breast cancer avoid chemotherapy.
The test, Oncotype DX, had already demonstrated its ability to predict whether chemotherapy would benefit women with breast cancer that has not spread to lymph nodes, known as node-negative breast cancer.
Credit: SWOG Cancer Research Network
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination - of irinotecan, cetuximab, and vemurafenib - is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.
Results of the SWOG study, led by Scott Kopetz, MD, PhD, of M.D. Anderson Cancer Center, are published in the
Journal of Clinical Oncology. The findings are expected to change the standard of care for patients with colorectal cancer that is metastatic - when tumors spread to other parts of the body - and includes a mutation in the BRAF gene called V600E. This mutation is found in about 10 percent of metastatic colorectal cancers and tumors with the mutation rarely responds to treatment, resulting in
What’s new in breast cancer research? SABCS20 goes virtual
Hutch scientists share findings on treatment, imaging, CAR T therapy, COVID-19’s impact on cancer patients and more December 18, 2020 • By Diane Mapes / Fred Hutch News Service The 2020 San Antonio Breast Cancer Symposium, held virtually this year because of COVID-19, featured the latest research to inform the care of people with breast cancer. Getty Images stock photo
The San Antonio Breast Cancer Symposium was a virtual event this pandemic year, allowing thousands of breast cancer researchers, oncologists and patient advocates from around the world to log in for four full days of science and resilience writ large.
Landmark study finds how often cancer patients develop osteonecrosis of the jaw
A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has found that 2.8 percent of patients on average develop osteonecrosis of the jaw, or ONJ, within three years of starting a common treatment for cancer that has spread to the bone.
Appearing in
JAMA Oncology, the findings are important because the treatment, zoledronic acid, is prescribed to tens of thousands of patients whose cancer has spread to the bone. Almost all forms of cancer can spread, or metastasize, to bone but the most common are lung, breast, and prostate cancers and multiple myeloma. Zoledronic acid can protect bone, but is associated with a risk of ONJ, which causes exposed bone in the jaw that does not heal. This causes inflammation and pain in the mouth, and people with ONJ may have troub
E-Mail
IMAGE: Dr. Catherine Van Poznak is the co-chair of a new SWOG Cancer Research Network trial that details, for the first time, the incidence of a common bone disease in cancer. view more
Credit: University of Michigan Rogel Cancer Center
PORTLAND, OR - A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has found that 2.8 percent of patients on average develop osteonecrosis of the jaw, or ONJ, within three years of starting a common treatment for cancer that has spread to the bone.